ELV - Elevance Health Inc.
NYSE
->
Healthcare
->
Healthcare Plans
Indianapolis,
United States
Type: Equity
ELV price evolution
ELV
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | ||||
| Long term investments | ||||
| Property, plant & equipment | $4505 | $4450 | $4451 | $4359 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $116533 | $112988 | $111894 | $108928 |
| Current liabilities | ||||
| Accounts payable | $6255 | $5760 | $5658 | $6910 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8715 | $8885 | $10133 | $1874 |
| Long term debt | $24688 | $24561 | $21976 | $23246 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $72758 | $70797 | $71286 | $69622 |
| Shareholders' equity | ||||
| Retained earnings | $35157 | $34575 | $33088 | $31749 |
| Other shareholder equity | -$659 | -$670 | -$674 | $39306 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | ||||
| Long term investments | ||||
| Property, plant & equipment | $4359 | $4316 | $4547 | $4129 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $108928 | $102772 | $97460 | $86615 |
| Current liabilities | ||||
| Accounts payable | $6910 | $5035 | $4970 | $5493 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1874 | $6800 | $7841 | $7150 |
| Long term debt | $23246 | $22349 | $21157 | $19335 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $69622 | $66465 | $61400 | $53416 |
| Shareholders' equity | ||||
| Retained earnings | $31749 | $29724 | $27088 | $23802 |
| Other shareholder equity | $39306 | -$2503 | -$670 | -$797 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $45145 | $43646 | $42577 | $42647 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $43433 | $40620 | $39373 | $41365 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $365 | $685 | $690 | $170 |
| Interest expense | -$300 | -$280 | -$265 | -$259 |
| Net income | ||||
| Net income | $1016 | $2300 | $2246 | $856 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $171340 | $156595 | $138639 | $121867 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $161843 | $148105 | $129484 | $114156 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $1724 | $1712 | $1830 | $1666 |
| Interest expense | -$1030 | -$851 | -$798 | -$784 |
| Net income | ||||
| Net income | $5987 | $5894 | $6104 | $4572 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3529 | -$3128 | -$2310 | -$5572 |
| Financing activities | ||||
| Dividends paid | -$1135 | -$757 | -$379 | -$1395 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$215 | $700 | $32 | -$3349 |
| Effect of exchange rate | $2 | -$5 | -$1 | |
| Change in cash and equivalents | $1340 | -$29 | -$300 | -$861 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$5572 | -$4560 | -$9638 | -$7324 |
| Financing activities | ||||
| Dividends paid | -$1395 | -$1229 | -$1104 | -$954 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$3349 | -$1318 | $423 | -$2567 |
| Effect of exchange rate | -$1 | -$14 | -$10 | $7 |
| Change in cash and equivalents | -$861 | $2507 | -$861 | $804 |
News
Fundamentals
| Market cap | $101.05B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 231.93M |
| Revenue | $174.01B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $6.42B |
| Revenue Q/Q | 13.03% |
| Revenue Y/Y | 13.55% |
| P/E ratio | 15.74 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.58 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $27.67 |
|---|---|
| ROA | 5.70% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |